Conveglipron

What It Is

Conveglipron (developmental code HDM1002) is an investigational oral, once-daily small molecule that activates the GLP-1 receptor, being developed by China-based Huadong Medicine for obesity and type 2 diabetes. Unlike injectable GLP-1 peptides such as semaglutide and tirzepatide, conveglipron is a small-molecule full agonist of the GLP-1 receptor designed to be taken as a pill, placing it in the same emerging class as Eli Lilly's orforglipron and the discontinued Pfizer candidate danuglipron. The appeal of an oral GLP-1 is convenience and scalability: pills are easier to manufacture, distribute, and store at scale than injectable peptides, and they avoid needles. In a published first-in-human single-ascending-dose study (Diabetes, Obesity & Metabolism, 2025) and a randomized, double-blind, placebo-controlled multiple-ascending-dose Phase 1b study in Chinese adults with overweight or obesity (Obesity, 2026), conveglipron was generally well tolerated over 28 days of dosing and produced dose-dependent weight loss, with participants in the higher dose groups losing roughly 4.9% to 6.8% of body weight by day 28. The most common side effects were gastrointestinal — mostly mild nausea and vomiting — consistent with the GLP-1 drug class. As of early 2026, conveglipron was reported to be in Phase 3 trials for type 2 diabetes and Phase 2 trials for obesity in China. It is investigational, is not approved by the FDA or, for obesity, by any regulator, and is not a marketed, prescribed, or compounded consumer product. Despite acting at the same receptor as GLP-1 peptides, conveglipron is a small molecule, not a peptide.

Why Researchers Study It

Conveglipron targets one of obesity and diabetes medicine's biggest practical goals: delivering GLP-1 efficacy in a low-cost, scalable oral small molecule rather than an injectable peptide. Researchers are interested in whether an oral small-molecule GLP-1 agonist can approach the weight loss and glucose control of injectable GLP-1 drugs while remaining tolerable, and how it stacks up against the leading oral GLP-1 candidate orforglipron. Because pills can be manufactured far more cheaply and at greater volume than peptides, a successful oral GLP-1 could dramatically expand global access — making conveglipron part of a closely watched race to define the next generation of obesity therapeutics beyond the injectable era.

Proposed Mechanisms

• Acts as a selective, potent small-molecule full agonist of the GLP-1 receptor
• Stimulates glucose-dependent insulin secretion to improve blood-sugar control
• Promotes satiety and reduces food intake through central GLP-1 signaling
• Slows gastric emptying to prolong post-meal fullness
• Designed for oral, once-daily dosing rather than injection

Evidence Snapshot

Commonly Discussed Benefits

Safety & Cautions

Comparisons

See how Conveglipron compares to related peptides:

Calculator Tools

Use our research tools to explore dosing and reconstitution data:

Citations

1. [1] Xu et al. — HDM1002 in Chinese Adults With Overweight/Obesity: A Randomized, Placebo-Controlled, Ascending-Dose Phase 1b Study (Obesity, 2026) PubMed
2. [2] Pu J. et al. — First-in-human study of HDM1002, a GLP-1 receptor agonist: single-dose safety, tolerability, PK and PD in healthy volunteers (Diabetes, Obesity & Metabolism, 2025) PubMed
3. [3] Huadong Medicine — Positive Phase I Results for Oral Small Molecule GLP-1 Receptor Agonist HDM1002 (PR Newswire) PubMed

Related Peptides